Evaluation the Effect of Adding Galantamine to Second Generation Antipsychotics
Phase 2
Recruiting
- Conditions
- Schizophrenia.Schizophrenia
- Registration Number
- IRCT20181117041682N2
- Lead Sponsor
- Ahvaz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
Diagnosis of schizophrenia based on the DSM-5
Age of 18-55 years
Get at least one second-generation anti-psychotic drug within the dose range
Having a score of at least 15 in the subgroup of negative marks on the PANSS assessment scale
Exclusion Criteria
Other disorders in axis 1
The presence of cardiac disorders, liver disorders, kidney disorders and etc.
History of allergy to second-generation antipsychotics
Positive test for amphetamines or methamphetamines at initiate time of admission
Pregnancy or breastfeeding
Simultaneous treatment with anticholinergic drugs
The existence of suicidal thoughts
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method egative sign of Schizophrenia. Timepoint: at the start of treatment, weeks 2, 4 and 8 of treatment. Method of measurement: Oveall scale score PANS.
- Secondary Outcome Measures
Name Time Method